Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Pembrolizumab, Gemcitabine, Cisplatin, Consolidative Surgery; Drug · Procedure
Lead sponsor: Jason R. Brown; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 9
States / cities: Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more

Conditions: Liver Transplantation
Interventions: tacrolimus modified release (MR), tacrolimus; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Up to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Atlanta, Georgia • Indianapolis, Indiana • New Orleans, Louisiana + 2 more

Conditions: Hepatitis B, Chronic
Interventions: IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Cleveland, Ohio

Conditions: Generalized Epidermolysis Bullosa Simplex
Interventions: AC-203, Vehicle; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Alcohol Use Disorder
Interventions: Brief Negotiated Interview (BNI), BNI+facilitated provision of MAUD, Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Sickle Cell Disease
Interventions: Collaborative Care Model, Promoting Resilience in Stress Management; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumors, Advanced Solid Tumor
Interventions: BG-C0902; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Houston, Texas • San Antonio, Texas • Fairfax, Virginia

Conditions: Sleep Apnea, Obstructive
Interventions: CPAP + Peer Support, CPAP + Individual Education; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes
Interventions: Home Visitiation, Education; Behavioral
Lead sponsor: Delta Health Alliance; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Leland, Mississippi

Conditions: Cancer, Neoplasms
Interventions: GSK2816126; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Lung Cancer
Interventions: Questionnaire, Patient Interview, Audio recordings of clinical consultations, 2-hour empathic communication skills training, Standardized Patient Assessments, Training evaluation, Patient recruitment; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Fibrosing Interstitial Lung Disease
Interventions: Nerandomilast, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Alemtuzumab; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: La Jolla, California • La Verne, California • Aurora, Colorado + 4 more

Conditions: Advanced Malignancies, Advanced Cancer
Interventions: PF-07994525, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 27
States / cities: Denver, Colorado • New Haven, Connecticut • North Haven, Connecticut + 11 more

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance
Interventions: Egg breakfast, Egg breakfast with high saturated fat, Cereal breakfast, Cereal breakfast with high saturated fat; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Immunization, Reminder Systems
Interventions: Parent Only Phone Call, Parent and Adolescent Phone Call; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 17 Years · Female only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Moderate to Severe Psoriatic Arthritis
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Huntington Beach, California • Duncansville, Pennsylvania • Philadelphia, Pennsylvania + 5 more

Conditions: Healthy Volunteer
Interventions: ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: BGB-21447, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Iowa City, Iowa • Houston, Texas • Seattle, Washington

Conditions: Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
Interventions: Ramucirumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Months to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Monrovia, California • Orange, California + 18 more

Conditions: Anaemia
Interventions: Daprodustat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 259 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Anaheim, California • Overland Park, Kansas • Las Vegas, Nevada + 1 more

Conditions: AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
Interventions: APG-115, 5-azacitidine; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: Gilbert, Arizona • Denver, Colorado • Durham, North Carolina + 5 more

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Histotripsy, Durvalumab, Biopsy; Device · Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hiv, HIV Infections, AIDS
Interventions: Stigma Reduction Intervention; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 99 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Promoting Alcohol Treatment Engagement Post-hospitalization

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Group-based Peer Support Versus Individual Education for Patients Undergoing CPAP Treatment

Pilot of Home Visitation Services for Patients With a Diabetes Diagnosis

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Clinician-Patient Communication in Lung Cancer Care

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method

Study of Adolescent Immunization Recall Systems

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

Standardized Patients to Measure and Address Intersectional Stigma